Valuation: Eli Lilly and Company

Capitalization 855B 731B 675B 637B 1,182B 78,979B 1,209B 7,972B 3,108B 38,094B 3,208B 3,140B 136,039B P/E ratio 2026 *
28.1x
P/E ratio 2027 * 23.6x
Enterprise value 870B 744B 687B 648B 1,203B 80,379B 1,230B 8,114B 3,164B 38,769B 3,264B 3,195B 138,450B EV / Sales 2026 *
10.7x
EV / Sales 2027 * 8.96x
Free-Float
99.81%
Yield 2026 *
0.7%
Yield 2027 * 0.78%
1 day+0.08%
1 week+2.10%
Current month+3.85%
1 month-5.28%
3 months-10.19%
6 months+11.67%
Current year-11.12%
1 week 898.45
Extreme 898.4501
963.76
1 month 877.11
Extreme 877.11
1,003.22
Current year 877.11
Extreme 877.11
1,133.95
1 year 623.78
Extreme 623.78
1,133.95
3 years 363.33
Extreme 363.33
1,133.95
5 years 178.58
Extreme 178.5779
1,133.95
10 years 64.18
Extreme 64.18
1,133.95
Manager TitleAgeSince
Chief Executive Officer 58 31/12/2016
Director of Finance/CFO 49 08/09/2024
Chief Tech/Sci/R&D Officer 52 -
Director TitleAgeSince
Director/Board Member 65 31/12/2004
Director/Board Member 69 31/03/2009
Director/Board Member 54 11/12/2011
Change 5d. change 1-year change 3-years change Capi.($)
+0.20%+2.10%+26.73%+159.36% 855B
+0.00%-0.71%+59.84%+46.12% 581B
+0.38%+1.70%+18.10%+31.48% 376B
+0.31%0.00%+35.09%+15.85% 320B
+0.71%+3.09%+53.92%+32.59% 318B
-0.41%+1.50%+49.77%+9.21% 303B
+0.61%+2.69%+45.22%+41.65% 295B
+1.66%+2.20%+22.16%+40.38% 192B
+0.39%+1.70%+35.00%+70.43% 176B
+2.19%+3.59%-40.53%-54.96% 165B
Average +0.65%+0.57%+30.53%+39.21% 358.17B
Weighted average by Cap. +0.44%+0.77%+34.89%+60.43%

Financials

2026 *2027 *
Net sales 81.67B 69.81B 64.53B 60.84B 113B 7,547B 115B 762B 297B 3,640B 306B 300B 12,999B 94.91B 81.13B 74.99B 70.7B 131B 8,770B 134B 885B 345B 4,230B 356B 349B 15,106B
Net income 30.39B 25.98B 24.01B 22.64B 42.02B 2,808B 42.98B 283B 111B 1,355B 114B 112B 4,837B 36.2B 30.94B 28.6B 26.97B 50.05B 3,345B 51.2B 338B 132B 1,613B 136B 133B 5,762B
Net Debt 15.15B 12.95B 11.97B 11.28B 20.94B 1,400B 21.42B 141B 55.09B 675B 56.84B 55.64B 2,411B -3.97B -3.39B -3.14B -2.96B -5.49B -367B -5.61B -37.03B -14.44B -177B -14.9B -14.58B -632B
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (74%): products for treating osteoporosis, diabetes, and growth problems; - oncology (14.4%); - immunology diseases (8.1%); - neurology (2.1%): primarily drugs used in treating depression and schizophrenia; - other (1.4%). Net sales are distributed geographically as follows: the United States (66.7%), Europe (17.7%), Japan (3.2%), China (3%) and other (9.4%).
Employees
50,000
Date Price Change Volume
09/04/26 955.19 $ +0.20% 1,672,549
08/04/26 953.30 $ +2.39% 2,567,998
07/04/26 931.09 $ +0.43% 2,726,863
06/04/26 927.06 $ -0.91% 1,821,082
02/04/26 935.58 $ -1.98% 2,727,128
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
955.19USD
Average target price
1,209.21USD
Spread / Average Target
+26.59%

Quarterly revenue - Rate of surprise